Jeffrey V. Poulton - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Jeffrey V. Poulton has filed 1 SEC Form 4 filing across 1 company in the last 90 days - selling. Lifetime open-market sales: $5.40M.
Profile
Jeffrey V. Poulton is Director at CervoMed Inc. (CRVO). SEC records also connect Poulton to ALNYLAM PHARMACEUTICALS, INC. (ALNY). Poulton has reported 9 insider filings with the SEC since 2024. The most recent filing was in June 2026.
| Role | Director |
|---|---|
| Notability | 34/100 |
Board memberships
- CervoMed Inc.
- ALNYLAM PHARMACEUTICALS, INC.
Reported roles
- Director
- EVP, Chief Financial Officer
Awards & honors
- Leadership in RNAi therapeutics
- Financial management in biotech companies
Trading Pattern
InsiderAlpha's records for Jeffrey V. Poulton go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Jeffrey V. Poulton has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at CervoMed Inc. (CRVO) - 2 filings, 2025 to 2026
- EVP, Chief Financial Officer at ALNYLAM PHARMACEUTICALS, INC. (ALNY) - 7 filings, 2024 to 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 223 | $325.67 | $73K |
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 291 | $324.88 | $95K |
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 818 | $323.84 | $265K |
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 374 | $323.01 | $121K |
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 309 | $321.82 | $99K |
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 230 | $320.81 | $74K |
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 109 | $320.01 | $35K |
| 2026-03-06 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 114 | $319.03 | $36K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 53 | $332.64 | $18K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 129 | $331.93 | $43K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 112 | $330.85 | $37K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 234 | $329.71 | $77K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 138 | $328.71 | $45K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 454 | $327.67 | $149K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 541 | $326.81 | $177K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 356 | $325.63 | $116K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 124 | $324.65 | $40K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | S - Open-market sale | 65 | $323.62 | $21K |
| 2026-03-05 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | A - Grant or award | 4.8K | $0.00 | |
| 2026-03-02 | ALNY | ALNYLAM PHARMACEUTICALS, INC. | M - Option exercise | 1.9K | $0.00 |
Companies - Last 90 Days
- CervoMed Inc. (CRVO) - 1 filing, last 2026-06-10
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Jeffrey V. Poulton has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Joshua S. Boger - $3.00M of CRVO open-market activity in the last 12 months
- Sylvie Gregoire - $283K of CRVO open-market activity in the last 12 months
- John J. Alam - $283K of CRVO open-market activity in the last 12 months
- Matthew Winton - $117K of CRVO open-market activity in the last 12 months
- William Robert Elder - $55K of CRVO open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Jan Philipp Jenisch
- Marc Johnson
- James Jones
- Andrew T. Kaplan
- A. J. Kazimi
- Michael John Kazley
- Kennedy Lewis Investment Holdings II LLC
- KENNEDY LEWIS MANAGEMENT LP
Frequently Asked Questions
Who is Jeffrey V. Poulton?
Jeffrey V. Poulton is Director at CervoMed Inc. (CRVO). SEC records also connect Poulton to ALNYLAM PHARMACEUTICALS, INC. (ALNY). Poulton has reported 9 insider filings with the SEC since 2024. The most recent filing was in June 2026.…
How many SEC Form 4 filings has Jeffrey V. Poulton submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Jeffrey V. Poulton been buying or selling stock?
Recorded transactions: 0 open-market purchases and 44 open-market sales ($5.40M) across all tracked filings.
Where can I see all of Jeffrey V. Poulton's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Jeffrey V. Poulton profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.